ARHGAP35

Across TCGA pan-cancer cohorts, ARHGAP35 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ARHGAP35 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARHGAP35 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGAP35 expression acts as an unfavorable survival marker, although some lineages such as UCEC and KIRC show a favorable association.

UCEC, LUAD, and SKCM are the cancer types where ARHGAP35 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.939	0.818	.002	36	view →
LUAD	DFS	Median	All	0.498	0.796	<.001	22	view →
SKCM	DFS	Median	III,IV	0.213	0.621	.001	18	view →
LGG	DFS	Median	All	0.149	0.834	<.001	14	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
KIRC	DFS	Median	IV	1.000	0.309	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ARHGAP35–UCEC (DFS)

Open the UCEC breakdown →